Results from a recent trial indicated continuously decreasing risks of all forms of retinal vascular occlusion and retinal vein occlusion for 5 years after treatment.
Kevin Allan, MD, PhD
Advertisement
Dr. Allan is a resident at the Cleveland Clinic Cole Eye Institute.
Articles by Kevin Allan, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Brensocatib Patient Selection Evolves 1 Year After FDA Approval
2
CKM Syndrome, Artery Damage Prevalence Higher in Young Adults than Previously Believed
3
ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD
4
Why Mentorship Matters Most for Dermatology Trainees
5